TROG 16.03 (CORE)
Primary sponsor: The Institute of Cancer Research (UK)
Collaboratiing group: Trans Tasman Radiation Oncology Group (TROG)
Title
A randomised trial of Cnventional care versus Radioablation (stereotactic body radiotherapy) for Extracranial oligometastases
Summary
CORE is a phase II/III, multicentre, non-blinded, randomised controlled trial in patients with breast, prostate or non-small cell lung cancer (NSCLC) primary cancer to evaluate if the addition of stereotactic body radiotherapy (SBRT) to standard therapy improves progression-free survival outcomes in patients with extra-cranial metastases that have spread from either their lung, breast and/or prostate cancer.
Final Accrual
235
Trial Status
Closed to accrual, February 2019
Trial chairperson
A/Prof David Pryor, Princess Alexandra Hospital, QLD
A/Prof Farshad Foroudi, Austin Health - Olivia Newton John Cancer and Wellness Centre, VIC
Trial contact
Patrick Wheeler
TROG Trial Coordinating Centre
Phone: +61 2 4014 3903
Email: CORE@trog.com.au
Trial resources for TROG members
|